• Mei Zhang, Ran Wu, Min Jia, Shaoqin Sun, Lei Zhang, and Ting Tang.
• Guizhou University of Traditional Chinese Medicine, Guiyang, China.
• Medicine (Baltimore). 2023 Oct 13; 102 (41): e35659e35659.

RationaleDermatologic toxicity has been reported as the most common immune-related side effect of programmed cell death 1 inhibitors. Previous reports related to Sintilimab include rash, pruritus, vitiligo, Stevens-Johnson syndrome, toxic epidermal necrolysis, and so on.Patient ConcernsA 66-year-old man was treated with Sintilimab as monotherapy for sigmoid colon cancer. After the second prescription, he developed a more severe and widespread rash.DiagnosesThe diagnose of erythema multiforme drug eruption induced by Sintilimab was considered.InterventionsThe patient received intravenous and oral methylprednisolone, routine antihistamines and topical gluccorticoids.OutcomesThe patient's symptoms were gradually relieved during hospitalization and was discharged following resolution of symptoms. He refused to continue using Sintilimab.LessonsThis is the first reported case of Sintilimab-induced erythema multiforme drug eruption. It is advisable to inform patients of potential dermatologic toxicity that may occur after using immune checkpoint inhibitors, so that we may prevent the further development of it and avoid the discontinuation of immune checkpoint inhibitors.Copyright © 2023 the Author(s). Published by Wolters Kluwer Health, Inc.

22 keywords...

hide…